<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293084</url>
  </required_header>
  <id_info>
    <org_study_id>CFF Account #LAUBE06A0</org_study_id>
    <nct_id>NCT01293084</nct_id>
  </id_info>
  <brief_title>Hypertonic Saline and Mucociliary Clearance in Children</brief_title>
  <official_title>Acute Inhalation of Hypertonic Saline Does Not Improve Mucociliary Clearance in All Children With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Foundation Therapeutics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previously, the investigators and others have shown that mucociliary clearance (MCC) is
      defective in patients with cystic fibrosis (CF) and it is now thought that alterations in
      airway mucus rheology figure prominently in the impairment. Mucociliary clearance works by
      trapping toxic particles, bacteria and viruses in the lung mucus and then quickly removing
      the mucus out of the lungs. Defects in MCC typically lead to the accumulation of mucus in the
      airways, and this in turn is associated with acute infections, chronic bacterial colonization
      and chronic inflammation. One treatment strategy that is gaining acceptance as an important
      therapy for improving MCC in adults with CF is the inhalation of the osmotic stimulus,
      hypertonic saline (HS). A number of studies have shown that acute inhalation of HS (7%
      saline) significantly improves MCC in adults with CF and results from a recent study indicate
      that two weeks of inhaling HS leads to a significant increase in MCC that is sustained for 8
      hours post inhalation and is associated with significant improvements in FEV1, FVC and
      FEF25-75 values. Since MCC in patients with CF appears to be impaired by adulthood, any drug
      that disrupts or slows the impairment in childhood could prove enormously beneficial in the
      long-term prognosis of the disease. Nevertheless, no studies have been conducted to determine
      if HS treatment improves MCC in children with CF. This is most problematic for physicians who
      care for children with CF who have normal FEV1 and FVC values, since it is unclear if they
      should treat these children with HS or not. This research study is designed to begin to
      answer this question. The investigators hypothesize that acute inhalation of hypertonic
      saline (7%) will improve MCC in CF children with normal pulmonary function. Our hypothesis
      will be tested in a one-year clinical trial that will be randomized and placebo-controlled.
      Twelve children with CF who are 7-12 years old and have normal FEV1 and FVC values will
      participate. Our goal will be to compare MCC in these children on two study visits after
      acute inhalations of placebo (0.12% saline) or hypertonic saline (HS) (7% saline) aerosol.
      The investigators predict that MCC values after acute inhalation of 7% HS aerosol will be
      statistically significantly greater than after placebo inhalation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several studies report that mucociliary clearance (MCC) is impaired in adults with CF.
      Because MCC is an important airway defense mechanism, drugs that slow impairment of MCC in
      children could prove beneficial in the long-term prognosis of the disease. A few studies have
      shown that inhalation of hypertonic saline (HS) significantly improves MCC in adults with CF
      and improvement is associated with increases in pulmonary function and decreases in pulmonary
      exacerbations. Nevertheless, no studies have examined if HS improves MCC in CF children. This
      is problematic for physicians who care for CF children with normal pulmonary function, since
      it is unclear if they should treat with HS or not. This study was designed to begin to answer
      this question. Twelve children with CF (7-12 yrs; 5 males) and normal pulmonary function
      (FEV1 and FVC &gt; 90% of predicted values) participated in a screening visit and two study
      visits. On the screening visit, children underwent an induced sputum test. On the two study
      visits, they inhaled 0.12% saline (placebo), or HS, in a double-blind, randomized, cross-over
      study. Following inhalation of placebo or HS, patients inhaled the radioisotope 99mtechnetium
      and underwent sequential imaging of their lungs with a gamma camera for 90 min and
      approximately 24 hrs later. Mucociliary clearance was quantified at 60 min (MCC60), 90 min
      (MCC90) and 24 hrs (MCC24hrs) after inhalation of the radioisotope. Between the 60 min and 90
      min measurements, children coughed 30 times.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Mucociliary Clearance at 60 Minutes</measure>
    <time_frame>60 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Mucociliary Clearance at 90 Minutes</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>7% saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mL of 7% saline was inhaled once over a 20 minute period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.12% saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5mL 0.12% saline inhaled once during 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.12% saline</intervention_name>
    <description>5mL of 0.12% saline inhaled once over 20 minutes</description>
    <arm_group_label>0.12% saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7% saline</intervention_name>
    <description>5mL 7% saline inhaled once over 20 minutes</description>
    <arm_group_label>7% saline</arm_group_label>
    <other_name>hypertonic saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age 7-12 years old

          -  Diagnosis of cystic fibrosis by sweat chloride &gt; 60 meq/L, or presence of two CFTR
             mutations known to cause CF

          -  Routinely treated with the short-acting bronchodilator albuterol

          -  FEV1 &gt; 90% of predicted values

        Exclusion Criteria:

          -  FEV1 &lt; 90% of predicted values

          -  Routine use of hypertonic saline, mannitol, or amiloride

          -  Allergic bronchopulmonary aspergillosis (ABPA)

          -  Sputum colonization with Burkholderia cepacia or multiple antibiotic resistant
             organisms

          -  Evidence of a pulmonary exacerbation within past two weeks

          -  Treated with intravenous or oral antibiotics in the past two weeks for a pulmonary
             exacerbation

          -  Presence of an acute respiratory illness characterized by:

               -  Coughing above baseline values

               -  Wheezing

               -  Respiratory distress

               -  Hemoptysis

          -  Cannot perform the inhalation maneuvers that are required for drug inhalation or
             radioaerosol administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth L Laube, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <results_first_submitted>September 10, 2015</results_first_submitted>
  <results_first_submitted_qc>September 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 22, 2015</results_first_posted>
  <last_update_submitted>September 10, 2015</last_update_submitted>
  <last_update_submitted_qc>September 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Beth L. Laube</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>mucociliary clearance</keyword>
  <keyword>children</keyword>
  <keyword>cystic fibrosis</keyword>
  <keyword>hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Data could not be retrieved for the order of randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Children With CF</title>
          <description>Children with CF inhaled either 5 mL of 7% saline or 0.12% saline once over 20 minutes. On a second visit, the same children were crossed-over and inhaled either 0.12% saline or 7% saline over 20 minutes. The order of these visits was randomized but the sequence of the randomization is not known.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Children With CF</title>
          <description>Children with CF inhaled either 5 mL of 7% saline or 0.12% saline once over 20 minutes. On a second visit, the same children were crossed-over and inhaled either 0.12% saline or 7% saline over 20 minutes. The order of these visits was randomized but the sequence of the randomization is not known.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" lower_limit="8.9" upper_limit="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC (% predicted)</title>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107" lower_limit="101.5" upper_limit="116.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (% predicted)</title>
          <units>percent predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108" lower_limit="102.5" upper_limit="117.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>F508del homozygous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>F508heterozygous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Mucociliary Clearance at 60 Minutes</title>
        <time_frame>60 minutes</time_frame>
        <population>Participants that completed received both 7% saline and 0.12% saline over the duration of the study</population>
        <group_list>
          <group group_id="O1">
            <title>7% Saline</title>
            <description>5 mL of 7% saline was inhaled once over a 20 minute period.
7% saline: 5mL 7% saline inhaled once over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>0.12% Saline</title>
            <description>5mL 0.12% saline inhaled once during 20 minutes
0.12% saline: 5mL of 0.12% saline inhaled once over 20 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Mucociliary Clearance at 60 Minutes</title>
          <population>Participants that completed received both 7% saline and 0.12% saline over the duration of the study</population>
          <units>percentage mucociliary clearance</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6" lower_limit="12.3" upper_limit="27.4"/>
                    <measurement group_id="O2" value="15.4" lower_limit="12.4" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.2</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Mucociliary Clearance at 90 Minutes</title>
        <time_frame>90 minutes</time_frame>
        <population>Data for participants that completed and received both 7% saline and 0.12% saline.</population>
        <group_list>
          <group group_id="O1">
            <title>7% Saline</title>
            <description>5 mL of 7% saline was inhaled once over a 20 minute period.
7% saline: 5mL 7% saline inhaled once over 20 minutes</description>
          </group>
          <group group_id="O2">
            <title>0.12% Saline</title>
            <description>5mL 0.12% saline inhaled once during 20 minutes
0.12% saline: 5mL of 0.12% saline inhaled once over 20 minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Mucociliary Clearance at 90 Minutes</title>
          <population>Data for participants that completed and received both 7% saline and 0.12% saline.</population>
          <units>percentage mucociliary clearance</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="16.25" upper_limit="30.95"/>
                    <measurement group_id="O2" value="19.3" lower_limit="17.3" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.3</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>7% Saline</title>
          <description>5 mL of 7% saline was inhaled once over a 20 minute period.
7% saline: 5mL 7% saline inhaled once over 20 minutes</description>
        </group>
        <group group_id="E2">
          <title>0.12% Saline</title>
          <description>5mL 0.12% saline inhaled once during 20 minutes
0.12% saline: 5mL of 0.12% saline inhaled once over 20 minutes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Beth Laube Professor</name_or_title>
      <organization>Johns Hopkins Univeristy</organization>
      <phone>410-502-5791</phone>
      <email>blaube@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

